Formulary Drug Reviews: Plecanatide

Abstract

Get full access to this article

View all access options for this article.

References

Beitz

NDA approval letter: Trulance (plecanatide NDA 208745). Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208745Orig1s000ltr.pdf. Published January 19, 2017. Accessed January 23, 2017.

Trulance (plecanatide) [prescribing information]. New York, NY: Synergy Pharmaceuticals; 2017.

Plecanatide. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=plecanatide&Search=Search. Accessed January 21, 2017.

Synergy Pharmaceuticals. The plecanatide irritable bowel syndrome with constipation study (IBS-C) (CIBS). NLM Identifier: NCT01722318. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01722318?term=NCT01722318&rank=1. Updated January 13, 2015. Accessed January 21, 2017.

Synergy Pharmaceuticals. Synergy Pharmaceuticals announces acceptance of new drug application for plecanatide, a novel uroguanylin analog, in chronic idiopathic constipation [news release]. http://ir.synergypharma.com/press-releases/detail/1809/synergy-pharmaceuticals-announces-acceptance-of-new-drug. Published April 19, 2016. Accessed January 21, 2017.

Ford

Moayyedi

Lacy

et al ; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(suppl 1):S2-S26.

Paquette

Varma

Ternent

et al

The American Society of Colon and Rectal Surgeons’ clinical practice guideline for the evaluation and management of constipation. Dis Colon Rectum. 2016;59(6):479-492.

Linzess (linaclotide) [prescribing information]. Cambridge, MA: Forest Pharmaceuticals; 2016.

Camilleri

Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther. 2012;91(1):44-59.

10.

Jadallah

Kullab

Sanders

DS.

Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol. 2014;20(27):8898-8909.

11.

Pitari

GM.

Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther. 2013;7:351-360.

12.

Busby

Ortiz

Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide. Dig Dis Sci. 2014;59(5):1066-1067.

13.

Jarmuż

Zielkińska

Storr

Fichna

Emerging treatments in neurogastroenterology: perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil. 2015;27(8):1057-1068.

14.

Shailubhai

Comiskey

Foss

et al

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580-2586.

15.

Shailubhai

Palejwala

Arjunan

et al

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015;6(4):213-222.

16.

Shailubhai

Barrow

Talluto

et al

Plecanatide, a guanylate cyclase-C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study [poster P1174]. Poster presented at: 2011 American College of Gastroenterology Annual Scientific Meeting; October 28-November 8, 2011; Washington, DC. http://content.stockpr.com/synergypharma/db/Posters/93/poster_file/Synergy_Poster_P1174.pdf. Accessed May 16, 2016.

17.

Miner

Surowitz

Fogel

et al

Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial [abstract 925g]. Gastroenterology. 2013;144(5)(suppl 1):S163.

18.

Synergy Pharmaceuticals. The plecanatide chronic idiopathic constipation (CIC) study. NLM Identifier: NCT01429987. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01429987?term=plecanatide&rank=3. Updated April 26, 2016. Accessed January 21, 2017.

19.

Miner

Prieto

De La Portilla

et al

A phase III study of the efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC) (study-00) [abstract Sa1440]. Gastroenterology. 2016;150(4)(suppl 1):S316.

20.

Synergy Pharmaceuticals. 12-week study of plecanatide for CIC (the CIC3 study). NLM Identifier: NCT01982240. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT01982240?term=plecanatide&rank=1. Updated April 26, 2016. Accessed January 21, 2017.

21.

Miner

Lentz

Berenguer

et al

Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC): results from a multicenter phase III study (study-03) [abstract Su1214]. Gastroenterology. 2016;150(4)(suppl 1):s497-s498.

22.

Synergy Pharmaceuticals. 12-week study of plecanatide for CIC (the National CIC3 Study). NLM Identifier: NCT02122471. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02122471?term=plecanatide&rank=2. Updated April 26, 2016. Accessed January 21, 2017.

23.

Krause

Foehl

Koltun

Barrow

Griffin

Effect of plecanatide on stool consistency in the treatment of chronic idiopathic constipation (CIC): Results from two phase III studies [abstract Sa1444]. Gastroenterology. 2016;150(4)(suppl 1):S317.

24.

Nualart

Morgan

Berenguer

Nguyen

Barrow

Magnus

Effect of plecanatide on patient assessments in chronic idiopathic constipation (CIC): Results from two phase III studies [abstract Sa1443]. Gastroenterology. 2016;150(4)(suppl 1):S317.

25.

Synergy Pharmaceuticals. Open-label extension (OLE) study of plecanatide for chronic idiopathic constipation (CIC). NLM Identifier: NCT01919697. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01919697?term=plecanatide&rank=4. Updated August 11, 2016. Accessed January 21, 2017.